Neoliberal technocracy
Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
Bibliographic Data
| ID | 4597337 |
|---|---|
| Authors | Stuart Hogarth (0000-0001-6796-8815, King's College London, corresponding author) |
| Year | 2015 |
| Volume | 131 |
| Pages | 255-262 |
| Publication date | 2015-04-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Social Science & Medicine (JOURNAL) |
| Journal identifiers | ISSN: 0277-9536 • E-ISSN: 1873-5347 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.socscimed.2015.01.023 |
| PMID | 25661300 |
| OpenAlex | W2071009389 |
| Language | EN |
| Citations received | 9 |
| References cited | 12 |
Biology · Champion · Context (archaeology · Framing (construction · Pharmacogenomics · Political science · Politics · Public relations · Social science · Sociology · Technocracy · Technoscience · Biomedical Ethics and Regulation · Biotechnology and Related Fields · Engineering · Law · Medicine · Pharmaceutical Economics and Policy · Public Administration · Pharmacology
The translational lag narrative in policy discourse in the United States and the European Union
Competitive interdependence
Regulating Pharmaceutical Industry Marketing
Why translational medicine is, in fact, “new,” why this matters, and the limits of a predominantly epistemic historiography
Reimagining Health as a ‘Flow on Effect’ of Biomedical Innovation
The ratio of vision to data
Framing utility
Healthcare policy by other means
The social management of biomedical novelty
Designs on Nature
Regulatory Innovation
Tissue engineered technologies
Steering biomedicine
Pharmacopolitics
Neoliberal pharmaceutical science and the Chicago School of Economics
Pragmatic Objectivity and the Standardization of Engineered Tissues
The public policy of the European Union
Mutual transformation and the development of European policy spaces. The case of medicines licensing
The pharmaceuticalisation of society? A framework for analysis
| Unique citing works | 9 |
|---|---|
| Citations per year | 0,9 |
| Citation span | 2016 - 2026 (11) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 9 |